

550,632

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/090551 A2**

(51) International Patent Classification<sup>7</sup>: **G01N 33/68**

Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **NIKNEJAD, Anne** [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **REFFAS, Samia** [CH/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH).

(21) International Application Number:  
PCT/EP2004/003737

(22) International Filing Date: 7 April 2004 (07.04.2004)

(74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

## (30) Priority Data:

60/461,558	8 April 2003 (08.04.2003)	US
60/461,623	8 April 2003 (08.04.2003)	US
60/471,479	16 May 2003 (16.05.2003)	US
60/474,863	30 May 2003 (30.05.2003)	US
60/484,140	30 June 2003 (30.06.2003)	US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **GEN-OVA, LTD.**; Canon's Court, 22 Victoria Street, Hamilton, HM12 (BM).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, I-1230 Vienna (AT).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGOUD-PUY, Guilaine** [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, 1217 Meyrin (CH). **BEDERR, Nassima** [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **BOUGUELERET, Lydie** [FR/CH]; c/o GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **CUSIN, Isabelle** [FR/CH]; c/o GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **MAHE, Eve** [FR/CH]; c/o GeneProt, Inc., 2,

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS**

(57) Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.

WO 2004/090551 A2